Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2024
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2024
On October 24, 2024, the Company and Yoov Group Holding Limited ("Yoov") entered into a termination agreement and the anticipated reverse takeover transaction with Yoov was terminated.NEW YORK--(BUSINESS WIRE)--Dec. 20, 2024--Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2024.
紐約--(美國商業資訊)--2024年12月20日--致力於滿足腫瘤、自身免疫和傳染病領域未得到滿足的醫療需求的臨牀階段生物製藥公司Aptorum Group Limited（納斯達克股票代碼：APM）（「Aptorum Group」 或 「公司」）今天提供了業務最新情況，並公佈了截至2024年6月30日的六個月的財務業績。
"Our team and Yoov have spent considerable time and effort on the due diligence process, the negotiation of definitive terms, and the preparation of necessary transactional and listing documentation. However, current market conditions have introduced significant uncertainty regarding the availability of the required funding for the transaction. After careful consideration, our Board has determined that it is no longer in the best interests of our shareholders to proceed with this transaction. Despite this, we will continue to explore other business combination opportunities that we believe will enhance shareholder value," stated Mr. Ian Huen, Chief Executive Officer and Executive Director of Aptorum Group Limited.
「我們的團隊和Yoov在盡職調查流程、最終條款的談判以及必要的交易和上市文件的準備上花費了大量的時間和精力。但是，當前的市場狀況給交易所需資金的可用性帶來了很大的不確定性。經過仔細考慮，我們的董事會已確定進行本次交易不再符合股東的最大利益。儘管如此，我們將繼續探索其他業務合併機會，我們認爲這些機會將提高股東價值。」 Aptorum Group Limited首席執行官兼執行董事Ian Huen先生表示。
Corporate Highlights
企業亮點
On October 24, 2024, the Company and Yoov Group Holding Limited ("Yoov") entered into a termination agreement and the anticipated reverse takeover transaction with Yoov was terminated.
2024年10月24日，公司與Yoov集團控股有限公司（「Yoov」）簽訂了終止協議，預期與Yoov的反向收購交易終止。
Financial Results for the Six Months Ended June 30, 2024
截至2024年6月30日的六個月的財務業績
Aptorum Group reported a net loss of $2.7 million for the six months ended June 30, 2024 compared to $6.6 million for the same period in 2023. The decrease in net loss in the current period was driven by the decrease in operating expenses by $4.1 million due to the implementation of stringent budgetary control measures, as a result of the Company's exclusive emphasis on the previous anticipated RTO.
Aptorum集團報告稱，截至2024年6月30日的六個月淨虧損爲270萬美元，而2023年同期爲660萬美元。本期淨虧損的減少是由公司完全關注先前預期的RTO導致的運營費用減少了410萬澳元所致，這是由於公司完全關注先前預期的RTO，因此實施了嚴格的預算控制措施。
Research and development expenses were $2.0 million for the six months ended June 30, 2024 compared to $3.2 million for the same period in 2023. Before the Merger Agreement was terminated, we determined it was best to focus all of our attention and resources on completing the Merger and therefore paused the majority of our R&D activities during that time; following the termination of the Merger Agreement in the fourth quarter of fiscal 2024, we determined that searching for other business combination opportunities could maximize shareholder value, and our R&D activities remain suspended.
截至2024年6月30日的六個月中，研發費用爲200萬美元，而2023年同期爲320萬美元。在合併協議終止之前，我們確定最好將所有注意力和資源集中在完成合並上，因此在此期間暫停了大部分研發活動；在2024財年第四季度終止合併協議後，我們確定尋找其他業務合併機會可以實現股東價值最大化，我們的研發活動仍處於暫停狀態。
General and administrative fees were $0.3 million for the six months ended June 30, 2024 compared to $1.3 million for the same period in 2023. The decrease in general and administrative fees was primary due to the streamlining of our operations to focus on preparation for the Merger, which has since been abandoned.
截至2024年6月30日的六個月中，一般和管理費爲30萬美元，而2023年同期爲130萬美元。一般費用和管理費的減少主要是由於我們精簡了業務，將重點放在爲合併做準備上，但此後合併已被放棄。
Legal and professional fees were $0.4 million for the six months ended June 30, 2024 compared to $1.7 million for the same period in 2023. The decrease in legal and professional fees was attributed to the lack of non-routine activities that were present in the same period last year, such as the implementation of reverse stock split, and amendments to the memorandum and articles of association. The absence of such non-routine exercises in the current period has resulted in a decrease in legal and professional fees.
截至2024年6月30日的六個月中，法律和專業費用爲40萬美元，而2023年同期爲170萬美元。律師費和專業費用的減少歸因於缺乏去年同期的非常規活動，例如反向股票拆分的實施以及對備忘錄和公司章程的修訂。由於本期沒有此類非常規活動，法律和專業費用有所減少。
As of June 30, 2024, cash and restricted cash totaled approximately $0.8 million and total equity was approximately $13.2 million.
截至2024年6月30日，現金和限制性現金總額約爲80萬美元，總權益約爲1,320萬美元。
|
APTORUM GROUP LIMITED UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS June 30, 2024 and December 31, 2023 (Stated in U.S. Dollars) | ||||||||
June 30, |
December 31, |
|||||||
ASSETS |
||||||||
Current assets: |
||||||||
Cash |
$ |
783,085 |
$ |
2,005,351 |
||||
Accounts receivable |
21,800 |
47,709 |
||||||
Amounts due from related parties |
3,595 |
961 |
||||||
Other receivables and prepayments |
725,616 |
422,071 |
||||||
Total current assets |
1,534,096 |
2,476,092 |
||||||
Property and equipment, net |
- |
1,663,926 |
||||||
Operating lease right-of-use assets |
- |
182,057 |
||||||
Long-term investments |
16,098,846 |
16,098,846 |
||||||
Intangible assets, net |
- |
147,347 |
||||||
Long-term deposits |
71,823 |
71,823 |
||||||
Total Assets |
$ |
17,704,765 |
$ |
20,640,091 |
||||
LIABILITIES AND EQUITY |
||||||||
LIABILITIES |
||||||||
Current liabilities: |
||||||||
Amounts due to related parties |
$ |
79,180 |
$ |
79,180 |
||||
Accounts payable and accrued expenses |
1,148,235 |
1,894,341 |
||||||
Operating lease liabilities, current |
89,145 |
125,232 |
||||||
Total current liabilities |
1,316,560 |
2,098,753 |
||||||
Operating lease liabilities, non-current |
62,718 |
99,485 |
||||||
Convertible notes to a related party |
3,148,500 |
3,058,500 |
||||||
Total Liabilities |
$ |
4,527,778 |
$ |
5,256,738 |
||||
Commitments and contingencies |
- |
- |
||||||
EQUITY |
||||||||
Class A Ordinary Shares ($0.00001 par value, 9,999,996,000,000 shares authorized, 3,674,164 shares issued and outstanding as of June 30, 2024; 2,937,921 shares issued and outstanding as of December 31, 2023) |
$ |
37 |
$ |
31 |
||||
Class B Ordinary Shares ($0.00001 par value; 4,000,000 shares authorized, 1,796,934 shares issued and outstanding as of June 30, 2024; 2,243,776 shares issued and outstanding as of December 31, 2023) |
18 |
22 |
||||||
Additional paid-in capital |
93,470,186 |
93,018,528 |
||||||
Accumulated other comprehensive loss |
(9,762) |
(10,623) |
||||||
Accumulated deficit |
(70,805,518) |
(68,161,722) |
||||||
Total equity attributable to the shareholders of Aptorum Group Limited |
22,654,961 |
24,846,236 |
||||||
Non-controlling interests |
(9,477,974) |
(9,462,883) |
||||||
Total equity |
13,176,987 |
15,383,353 |
||||||
Total Liabilities and Equity |
$ |
17,704,765 |
$ |
20,640,091 |
||||
|
Aptorum 集團有限公司 未經審計的簡明合併資產負債表 2024 年 6 月 30 日和 2023 年 12 月 31 日 （以美元表示） | ||||||||
6月30日 |
十二月 31, |
|||||||
資產 |
||||||||
流動資產： |
||||||||
現金 |
$ |
783,085 |
$ |
2,005,351 |
||||
應收賬款 |
21,800 |
47,709 |
||||||
關聯方應付的款項 |
3,595 |
961 |
||||||
其他應收賬款和預付款 |
725,616 |
422,071 |
||||||
流動資產總額 |
1,534,096 |
2,476,092 |
||||||
財產和設備，淨額 |
- |
1,663,926 |
||||||
經營租賃使用權資產 |
- |
182,057 |
||||||
長期投資 |
16,098,846 |
16,098,846 |
||||||
無形資產，淨額 |
- |
147,347 |
||||||
長期存款 |
71,823 |
71,823 |
||||||
總資產 |
$ |
17,704,765 |
$ |
20,640,091 |
||||
負債和權益 |
||||||||
負債 |
||||||||
流動負債： |
||||||||
應付給關聯方的金額 |
$ |
79,180 |
$ |
79,180 |
||||
應付賬款和應計費用 |
1,148,235 |
1,894,341 |
||||||
經營租賃負債，流動 |
89,145 |
125,232 |
||||||
流動負債總額 |
1,316,560 |
2,098,753 |
||||||
經營租賃負債，非流動 |
62,718 |
99,485 |
||||||
關聯方的可轉換票據 |
3,148,500 |
3,058,500 |
||||||
負債總額 |
$ |
4,527,778 |
$ |
5,256,738 |
||||
承諾和突發事件 |
- |
- |
||||||
公平 |
||||||||
A 類普通股（截至2024年6月30日，面值0.00001美元，已授權9,999,996,000,000股，已發行和流通3,674,164股；截至2023年12月31日已發行和流通的2,937,921股股票） |
$ |
37 |
$ |
31 |
||||
b 類普通股（面值0.00001美元；截至2024年6月30日，已授權4,000,000股，已發行和流通的1,796,934股；截至2023年12月31日已發行和流通的2,243,776股股票） |
18 |
22 |
||||||
額外的實收資本 |
93,470,186 |
93,018,528 |
||||||
累計其他綜合虧損 |
(9,762) |
(10,623) |
||||||
累計赤字 |
(70,805,518) |
(68,161,722) |
||||||
歸屬於Aptorum Group Limited股東的總權益 |
22,654,961 |
24,846,236 |
||||||
非控股權益 |
(9,477,974) |
(9,462,883) |
||||||
權益總額 |
13,176,987 |
15,383,353 |
||||||
負債和權益總額 |
$ |
17,704,765 |
$ |
20,640,091 |
||||
|
APTORUM GROUP LIMITED UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS For the six months ended June 30, 2024 and 2023 (Stated in U.S. Dollars) | ||||||||
For the six months ended |
||||||||
2024 |
2023 |
|||||||
Revenue |
||||||||
Healthcare services income |
$ |
- |
$ |
431,378 |
||||
Operating expenses |
||||||||
Costs of healthcare services |
- |
(426,063) |
||||||
Research and development expenses |
(2,038,923) |
(3,212,366) |
||||||
General and administrative fees |
(326,187) |
(1,263,019) |
||||||
Legal and professional fees |
(366,164) |
(1,738,566) |
||||||
Other operating expenses |
(137,233) |
(330,212) |
||||||
Total operating expenses |
(2,868,507) |
(6,970,226) |
||||||
Other income (expenses) |
||||||||
Loss on investments in marketable securities, net |
- |
(9,266) |
||||||
Interest expense, net |
(68,462) |
(93,478) |
||||||
Loss on disposal of subsidiaries |
(4,271) |
- |
||||||
Sundry income |
282,353 |
36,803 |
||||||
Total other income (expenses), net |
209,620 |
(65,941) |
||||||
Net loss |
$ |
(2,658,887) |
$ |
(6,604,789) |
||||
Less: net loss attributable to non-controlling interests |
(15,091) |
(1,117,685) |
||||||
Net loss attributable to Aptorum Group Limited |
$ |
(2,643,796) |
$ |
(5,487,104) |
||||
Net loss per share – basic and diluted |
$ |
(0.50) |
$ |
(1.43) |
||||
Weighted-average shares outstanding – basic and diluted |
5,339,608 |
3,849,621 |
||||||
Net loss |
$ |
(2,658,887) |
$ |
(6,604,789) |
||||
Other comprehensive income (loss) |
||||||||
Exchange differences on translation of foreign operations |
861 |
(7,485) |
||||||
Other comprehensive income (loss) |
861 |
(7,485) |
||||||
Comprehensive loss |
(2,658,026) |
(6,612,274) |
||||||
Less: comprehensive loss attributable to non-controlling interests |
(15,091) |
(1,117,685) |
||||||
Comprehensive loss attributable to the shareholders of Aptorum Group Limited |
(2,642,935) |
(5,494,589) |
||||||
|
Aptorum 集團有限公司 未經審計的簡明合併運營報表和綜合虧損報表 在截至2024年6月30日和2023年6月30日的六個月中 （以美元表示） | ||||||||
在結束的六個月中 |
||||||||
2024 |
2023 |
|||||||
收入 |
||||||||
醫療服務收入 |
$ |
- |
$ |
431,378 |
||||
運營費用 |
||||||||
醫療保健服務的成本 |
- |
(426,063) |
||||||
研究和開發費用 |
(2,038,923) |
(3,212,366) |
||||||
一般費用和管理費 |
(326,187) |
(1,263,019) |
||||||
法律和專業費用 |
(366,164) |
(1,738,566) |
||||||
其他運營費用 |
(137,233) |
(330,212) |
||||||
運營費用總額 |
(2,868,507) |
(6,970,226) |
||||||
其他收入（支出） |
||||||||
有價證券投資虧損，淨額 |
- |
(9,266) |
||||||
利息支出，淨額 |
(68,462) |
(93,478) |
||||||
出售子公司的損失 |
(4,271) |
- |
||||||
雜項收入 |
282,353 |
36,803 |
||||||
其他收入（支出）總額，淨額 |
209,620 |
(65,941) |
||||||
淨虧損 |
$ |
(2,658,887) |
$ |
(6,604,789) |
||||
減去：歸因於非控股權益的淨虧損 |
(15,091) |
(1,117,685) |
||||||
歸屬於Aptorum Group Limited的淨虧損 |
$ |
(2,643,796) |
$ |
(5,487,104) |
||||
每股淨虧損——基本虧損和攤薄後 |
$ |
(0.50) |
$ |
(1.43) |
||||
已發行股票的加權平均值——基本股和攤薄股票 |
5,339,608 |
3,849,621 |
||||||
淨虧損 |
$ |
(2,658,887) |
$ |
(6,604,789) |
||||
其他綜合收益（虧損） |
||||||||
國外業務翻譯方面的交換分歧 |
861 |
(7,485) |
||||||
其他綜合收益（虧損） |
861 |
(7,485) |
||||||
綜合虧損 |
(2,658,026) |
(6,612,274) |
||||||
減去：歸因於非控股權益的綜合虧損 |
(15,091) |
(1,117,685) |
||||||
歸屬於Aptorum Group Limited股東的綜合虧損 |
(2,642,935) |
(5,494,589) |
||||||
About Aptorum Group
關於Aptorum 集團
Aptorum Group Limited (Nasdaq: APM) is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The pipeline of Aptorum is also enriched through the co-development of PathsDx Test, a novel molecular-based rapid pathogen identification and detection diagnostics technology, with Accelerate Technologies Pte Ltd, commercialization arm of the Singapore's Agency for Science, Technology and Research.
Aptorum Group Limited（納斯達克股票代碼：APM）是一家臨牀階段的生物製藥公司，致力於發現、開發和商業化治療資產，以治療醫療需求未得到滿足的疾病，尤其是腫瘤學（包括孤兒腫瘤適應症）和傳染病。通過與新加坡科學、技術和研究局的商業化部門Accelerate Technologies私人有限公司共同開發的PathsDx Test（一種基於分子的新型快速病原體識別和檢測診斷技術），Aptorum的產品線也豐富了Aptorum的產品線。
For more information about the Company, please visit .
有關該公司的更多信息，請訪問。
Disclaimer and Forward-Looking Statements
免責聲明和前瞻性陳述
This press release does not constitute an offer to sell or a solicitation of offers to buy any securities of Aptorum Group.
本新聞稿不構成出售要約或徵集購買Aptorum集團任何證券的要約。
This press release includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute "forward-looking statements" within the meaning of the US Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential," or "continue," or the negative of these terms or other similar expressions. Aptorum Group has based these forward-looking statements, which include statements regarding projected timelines for application submissions and trials, largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations.
本新聞稿包括有關Aptorum Group Limited及其未來預期、計劃和前景的聲明，這些聲明構成《1995年美國私人證券訴訟改革法》所指的 「前瞻性陳述」。爲此，此處包含的任何非歷史事實陳述的陳述均可被視爲前瞻性陳述。在某些情況下，您可以通過諸如 「可能」、「應該」、「預期」、「預期」、「可能」、「打算」、「目標」、「項目」、「考慮」、「相信」、「估計」、「預測」、「潛在」 或 「繼續」 等術語來識別前瞻性陳述，或者這些術語或其他類似表述的否定值。Aptorum Group的這些前瞻性陳述，包括有關申請提交和審判的預計時間表的陳述，主要基於其當前對未來事件和趨勢的預期和預測，該公司認爲這些事件和趨勢可能會影響其業務、財務狀況和經營業績。
These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related to its announced management and organizational changes, the continued service and availability of key personnel, its ability to expand its product assortments by offering additional products for additional consumer segments, development results, the company's anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks more fully described in Aptorum Group's Form 20-F and other filings that Aptorum Group may make with the SEC in the future. As a result, the projections included in such forward-looking statements are subject to change and actual results may differ materially from those described herein.
這些前瞻性陳述僅代表截至本新聞稿發佈之日，受許多風險、不確定性和假設的影響，包括但不限於與其宣佈的管理和組織變革相關的風險、關鍵人員的持續服務和可用性、通過爲其他消費群體提供額外產品來擴大產品種類的能力、發展成果、公司的預期增長戰略、其業務的預期趨勢和挑戰以及對以下方面的預期：以及Aptorum集團的20-F表格以及Aptorum集團未來可能向美國證券交易委員會提交的其他文件中更全面地描述了其供應鏈的穩定性以及風險。因此，此類前瞻性陳述中包含的預測可能會發生變化，實際結果可能與此處描述的結果存在重大差異。
Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
由於新信息、未來事件或其他原因，Aptorum Group不承擔更新本新聞稿中包含的任何前瞻性陳述的義務。
This press release is provided "as is" without any representation or warranty of any kind.
本新聞稿 「按原樣」 提供，沒有任何形式的陳述或保證。
View source version on businesswire.com:
在 businesswire.com 上查看源版本：
Aptorum Group Limited
Investor Relations Department
investor.relations@aptorumgroup.com
+44 20 80929299
Aptorum 集團有限公司
投資者關係部
investor.relations@aptorumgroup.com
+44 20 80929299
Source: Aptorum Group Limited
來源：Aptorum 集團有限公司
譯文內容由第三人軟體翻譯。
